Date: 2016-02-01
Type of information: R&D agreement
Compound: novel immune-oncology targets
Company: Array BioPharma (USA - CO) Dana-Farber Cancer Institute (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On February 1, 2016, Dana-Farber Cancer Institute today announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma. The research team at Dana-Farber's Robert and Renée Belfer Center for Applied Cancer Science will work with Array scientists on novel immune-oncology targets with the goal of bringing innovative medicines to patients. The collaboration will leverage the Belfer Center's proprietary immuno-oncology platform. Combining Dana Farber's oncology expertise with the Array's proficiency in drug discovery provides a unique opportunity to accelerate drug discovery of effective medicines for patients with unmet medical need.
Financial terms: Financial terms of the agreement are not being disclosed.
Latest news:
